Summary of Erasca FY Conference Call (February 26, 2026) Company Overview - **Company**: Erasca (NasdaqGS:ERAS) - **Focus**: Development of therapies targeting RAS-driven cancers Key Points and Arguments RAS Targeting and Pipeline - Erasca is committed to targeting RAS mutations, which are present in 25%-30% of all solid tumors, indicating a significant unmet medical need [10][11] - The lead programs include: - **ERAS-0015**: A cyclophilin A binding molecular glue, expected to be best in class due to its higher binding affinity (8-21 fold) compared to competitors [14][15] - **ERAS-4001**: A pan-KRAS molecule designed to selectively target KRAS mutations while sparing HRAS and NRAS, potentially widening the therapeutic window [6][7] Clinical Data and Efficacy - Early clinical data suggests that ERAS-0015 shows activity at doses 10 times lower than daraxonrasib (RMC-6236), with responses observed at 8 mg QD compared to 80 mg for RMC-6236 [20][21] - The pharmacokinetics (PK) of ERAS-0015 indicate better bioavailability and a longer half-life, which may lead to improved tolerability and safety profiles [17][24] Combination Therapies - There is a strategic interest in exploring combinations of ERAS-0015 with anti-EGFR antibodies, which could enhance efficacy in treating colorectal cancer (CRC) and pancreatic cancer (PDAC) [25][56] - The potential for ERAS-4001 to combine with anti-EGFR therapies is also highlighted, as it may avoid overlapping toxicities seen with other treatments [49][56] Trial Updates - The **AURORAS-1 trial** is progressing well, with rapid enrollment and expected updates on safety, tolerability, and efficacy in the first half of the year [35][36] - The **BOREALIS-1 trial** is also on track, with updates anticipated in the second half of the year, focusing on similar parameters as AURORAS-1 [51][52] Intellectual Property and Competitive Landscape - Erasca has no intellectual property issues and holds a U.S. composition of matter patent extending to 2043, which is a significant advantage in the competitive landscape [40] - The company differentiates itself by having both pan-RAS and pan-KRAS therapies, positioning it uniquely in the market [57] Future Outlook - The company is optimistic about the upcoming data releases and believes that demonstrating efficacy in one or both lead assets will significantly enhance their value and impact on patient care [61][62] - The focus remains on the RAS/MAPK pathway, with ongoing development of additional therapies, including a bispecific EGFR antibody (ERAS-12) [58][59] Additional Important Insights - The discussion emphasizes the complexity of RAS biology and the potential for various therapeutic approaches to coexist rather than compete in a zero-sum game [9][11] - The company is aware of the challenges in combining therapies due to safety concerns but remains committed to exploring these avenues [48][56] This summary encapsulates the critical insights from the Erasca FY conference call, highlighting the company's strategic direction, pipeline developments, and the broader context of RAS-targeted therapies in oncology.

Summary of Erasca (ERAS) 2025 Conference Call Company Overview - **Company**: Erasca (ERAS) - **Event**: Bank of America Health Care Conference, May 14, 2025 - **Speaker**: Jonathan Lim, Chairman, Co-founder, and CEO of Erasca Key Updates and Developments 1. **Clinical Advancements**: - IND clearance of ERAS15, a pan RAS molecular glue, and IND submission of ERAS4001, a pan KRAS small molecule inhibitor, both ahead of schedule [4][21] - ERAS15 is positioned as the lead program, entering Phase 1 dose escalation followed by expansion cohorts [5][21] 2. **Strategic Partnerships**: - Seeking a strategic partner for Naporafenib to enhance development, regulatory, and commercial efforts [4] 3. **Financial Position**: - Cash runway extended from H2 2027 to H2 2028, providing over three years of cash resources [5][22] - More than $400 million on the balance sheet to advance RAS programs [22] Pipeline Focus 1. **ERAS15**: - Potential best-in-class pan RAS molecular glue with strong preclinical activity and low dose requirements for tumor regression [7][8] - High oral bioavailability and expected IP exclusivity through February 2043 [8][9] 2. **ERAS4001**: - KRAS selective inhibitor with good preclinical activity and high oral bioavailability [9][19] - Targets KRAS G12X and G13D mutations effectively [16] 3. **Combination Therapies**: - Promising data on combination treatments with anti-PD-1, showing complete tumor eradication in preclinical models [14][19] Mechanism of Action - ERAS15 binds to cyclophylline A (CYP A) with 8 to 21 fold higher affinity compared to competitors, leading to more potent RAS inhibition [10][11] - Demonstrated superior tumor regression with lower doses compared to existing treatments [11][12] Clinical Development Plan - Focus on major tumor types: colorectal, non-small cell lung cancer, and pancreatic cancer, as well as other tumor types with KRAS mutations [20] - Key milestones include IND filing and Phase I monotherapy data expected in 2026 [21] Additional Insights - ERAS15 shows a favorable pharmacokinetic profile with lower clearance and longer half-life compared to competitors [15][19] - No observed QTc prolongation in cardiovascular studies, indicating a favorable safety profile [19] This summary encapsulates the critical updates and strategic direction of Erasca as discussed during the conference call, highlighting the company's focus on advancing its RAS-targeting therapies and maintaining a strong financial position for future growth.